{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003572","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.600700+00:00","generated_at":"2026-06-04T13:20:11.610871+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Two Aclaris directors to depart at 2024 annual meeting","bullets":["Director Andrew Powell resigns effective June 6, 2024; no disagreement cited.","Director Bryan Reasons will not stand for re-election at June 6 annual meeting; no disagreement.","No replacements announced for the two departing board members."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003572","json":"https://secwatch.observer/filing/0001558370-24-003572.json","markdown":"https://secwatch.observer/filing/0001558370-24-003572.md","text":"https://secwatch.observer/filing/0001558370-24-003572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/0001558370-24-003572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/acrs-20240314x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:20:11.610871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8354fb7007","claim":"Andrew Powell resigned as Director at Aclaris Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Andrew Powell, a member of the board of directors (the “ Board ”) of Aclaris Therapeutics, Inc. (the “ Company ”), notified the Company of his intent to resign as a member of the Board, effective as of the date of the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 6, 2024 (the “ Annual Meeting ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/0001558370-24-003572-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"af923c3ea8","claim":"Bryan Reasons departed as Director at Aclaris Therapeutics, Inc..","evidence_excerpt":"Also on March 14, 2024, Bryan Reasons, a member of the Board, notified the Company that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/0001558370-24-003572-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}